The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Food Safety segment achieved 4% core growth, reaching market-level performance through improved commercial rigor and demand for indicator testing and culture media.

Adjusted EBITDA margins expanded to 22.8% due to disciplined cost control and a 9% sequential reduction in adjusted operating expenses.

Animal Safety revenue declined 8.7% on a core basis, primarily driven by third-party supplier transitions, raw material shortages, and documentation issues rather than underlying demand weakness.

Management is transitioning the commercial model from siloed regional operations to a unified, solutions-based global selling framework to better leverage the full product portfolio.

Operational efficiency efforts are focused on centralizing the supply chain and implementing AI-enabled logistics to reduce the current high reliance on manual processes and labor costs.

The company is reallocating resources by shifting to distribution partners in lower-impact markets to fund growth in high-priority geographic and customer segments.

The Petrifilm manufacturing transition remains on schedule for November 2026, with 100% of production equipment validated and SKU validation currently underway.

Management expects significant free cash flow improvement in fiscal 2027 as capital expenditures for Petrifilm facilities subside and duplicative manufacturing costs are eliminated.

Guidance for Q4 assumes a transition from currency tailwinds to headwinds and a measured recovery timeline for Animal Safety supply chain challenges.

Strategic R&D investment in a research-scale Petrifilm line is intended to accelerate entry into new markets such as pharmaceuticals and cosmetics by enabling custom SKU prototyping.

The divestiture of the genomics business, expected to close in Q2 fiscal 2027, is positioned to reduce net debt to adjusted EBITDA below 3x by the end of calendar 2026.

Global logistics disruptions, particularly near the Suez Canal, are driving high single-digit to low double-digit increases in freight and transportation costs.

A quality issue at a third-party supplier for sample collection products led to higher scrap rates and negative gross margins for that category this quarter.

Approximately 56% of operating expenses are currently tied to salaries and benefits, which management attributes to historical underinvestment in automation.

Animal Safety headwinds include a global vitamin A shortage and production transitions by key partners in instruments and sodium bicarb.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management clarified that Q3 issues were supply-side only, involving three specific partners transitioning manufacturing sites or facing raw material shortages.

The Q4 guidance remains 'meaningfully measured' as these external issues are not expected to be fully resolved within the next quarter.

Management expressed confidence in sustaining growth by optimizing the portfolio toward higher-margin products and realigning sales resources.

Customer sentiment is improving as food producers report volumes moving from 'declining' to 'flat,' though macro pressures like energy costs remain a factor.

Future margin gains are expected from in-sourcing Petrifilm, resolving sample collection quality issues, and improving purchase price variance through better supplier management.

A shift from legacy raw materials to finished goods is expected to lead to a 'meaningful decline' in inventory levels by fiscal 2027, further aiding margins.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.